Aptose Biosciences Inc has seen stable stock performance recently, with no major fluctuations over the past week.
Aptose Biosciences Inc (APS.TO) closed the last trading session at C$2.40, maintaining its position without any significant daily movement. Over the past week, the stock has remained stable, showing no percentage change. However, it has appreciated by approximately 9.59% over the past month and 18.81% year-to-date, indicating a generally positive trend.
Investor takeaway: Investors may find Aptose Biosciences' recent acquisition news relevant, although current stock performance remains stable without immediate catalysts influencing price action.
Advertisement
Aptose Biosciences Inc
APS.TO
APS.TO
Aptose Biosciences Inc
WealthAwesomeAdvertisement
Market cap
$6.13M
52W high
$2.59
52W low
$1.41
1W change
+0.00%
Beta
0.34
Analyst Price Targets
Based on analyst covering APS
Wall Street analysts forecast APS stock price to fall 1.7% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.36
-1.7% Upside
Current Price
C$2.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APS's historical volatility
30-Day Vol
52.7%
Annualized
90-Day Vol
48.9%
Annualized
Trend (90d)
-0.0%
Annualized drift
90d Mean
C$2.40
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.40 | C$2.00 – C$2.88 |
| 60 trading days | C$2.40 | C$1.86 – C$3.10 |
| 90 trading days | C$2.40 | C$1.75 – C$3.29 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Aptose Biosciences Inc's stock remains stable at C$2.40.
The stock has shown a year-to-date increase of 18.81%, reflecting a positive trend despite recent stability.
Bull case
The recent acquisition by Hanmi Pharmaceutical could give Aptose additional resources and market reach. This move may enhance its growth prospects in the healthcare sector.
Bear case
Despite the acquisition, the company’s negative profit margins and high return on equity (ROE) may raise concerns about its financial health and future profitability.
Recent Price Action
Advertisement
Aptose Biosciences Inc's stock closed at C$2.40, unchanged from the previous trading session. The stock has shown no significant movement, reflecting a steady performance over the past week. However, it has gained 9.59% over the past month and appreciated by 18.81% year-to-date, indicating a generally positive trend despite the recent lack of volatility.
Company News
On June 30, 2026, Aptose Biosciences announced the completion of its acquisition by Hanmi Pharmaceutical. This acquisition could provide the company with greater resources and market access, potentially enhancing its growth prospects in the competitive healthcare sector. Investors will be watching closely for any developments stemming from this acquisition.
Technical Picture
From a technical standpoint, Aptose Biosciences is currently trading above its 50-day moving average of C$2.25 by 6.4% and its 200-day moving average of C$2.14 by 12.3%. The stock's 52-week range is C$1.41 to C$2.59, with the current price representing 84% of this range. The stock's beta of 0.34 suggests it is less volatile than the broader market, which may appeal to risk-averse investors. The latest trading volume was 2,945 shares, slightly below the 20-day average volume of 3,425 shares, indicating lower trading activity.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
